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Background: After the diagnosis Non-Small-Cell Lung Carcinoma (NSCLC) has been established, consideration must
turn toward the stage of disease, because this will impact directly on management and prognosis. Staging is used to
predict survival and to guide the patient toward the most appropriate treatment regimen or clinical trial. Distinguishing
malignant involvement of the mediastinal lymph nodes (N2 or N3) from the hilar lymph nodes, or no lymph nodes
(N0 or N1) is critical, because malignant involvement of N2 or N3 lymph nodes usually indicates non–surgically
resectable disease. The purpose of this study was to examine and compare CT versus integrated F18-FDG PET/low dose
CT (FDG PET/CT) for mediastinal staging in NSCLC, and the desire was to safely distinguish between malignant and
benign lesions without the need for invasive procedures. All results were controlled for reproducibility.
Methods: 114 participants with NSCLC were included in a prospective cohort study. Blinded CT and FDG PET/CT
images were reviewed. The participants’ mediastinums were staged based on lymph node sizes (CT), or on FDG uptake
(FDG PET/CT). Reference standard was tissue sampling.
Results: We found that there was no measureable difference between CT and FDG PET/CT mediastinal staging results;
overall two-thirds of the participants in the study were correctly staged, and almost one-third of the participants were
falsely staged.
Conclusion: Neither CT nor FDG PET/CT could obviate the need for further invasive staging prior to thoracotomy in
patients with NSCLC; for that purpose, the results of both modalities were too meagre. Therefore, these patients still
depend on invasive staging methods. In our study, invasive staging was accomplished by mediastinoscopy. However,
today this is increasingly replaced by EBUS or EUS.
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After a diagnosis Non-Small-Cell Lung Carcinoma (NS
CLC) has been established, consideration must turn
toward the stage of disease, because this will impact
directly on management and prognosis. Staging is used
to predict survival and to guide the patient toward the
most appropriate treatment regimen or clinical trial.
The most significant dividing line is between those
patients who are candidates for surgery and those who
may benefit from chemotherapy, radiation therapy, or
both. The role of chemotherapy and radiation therapy
followed by surgery for advanced disease is controversial
[1]. Distinguishing malignant involvement of the ipsilat-
eral or contralateral mediastinal lymph nodes (N2 or N3)
from the ipsilateral hilar lymph nodes, or no lymph nodes
(N0 or N1) is critical, because malignant involvement of
N2 or N3 lymph nodes usually indicates non–surgically
resectable disease.
CT is the most widely available and commonly used
imaging modality for evaluation of the mediastinum in
lung cancer. The majority of reports evaluating the
accuracy of CT for mediastinal lymph node staging use
a short-axis diameter of ≥ 1 cm on a transverse CT
image as a threshold for abnormal nodes [1]. Using this
threshold, the median sensitivity and specificity of CT
for identifying mediastinal lymph node metastasis are
51%, and 86%, respectively [1]. These findings closely mir-
ror a previous analysis on the matter by Gould et al. [2].
F-18-FDG PET (FDG PET) scanning has both higher
sensitivity and higher specificity than CT scanning for
the evaluation of mediastinal lymph nodes. This holds
true even though there are no standardised quantitative
criteria for abnormal FDG PET scan findings in the
mediastinum [1]. Median estimates of sensitivity and
specificity for identifying mediastinal lymph node metas-
tasis are 74%, and 85%, respectively [1]. These findings
are slightly less optimistic than those previously reported
on the subject [2].
In some studies it has been claimed that the accuracy
of FDG PET imaging in the mediastinum depends on
the size of the nodes identified by CT. Indeed, Gould
et al. reported median sensitivity and specificity of FDG
PET scans of 100%, and 78%, respectively, in patients
with enlarged lymph nodes [2]. Conversely, the median
sensitivity and specificity of FDG PET scanning were
82%, and 93%, respectively, in patients with normal-
sized lymph nodes [2].
However, even though FDG PET has been used for me-
diastinal staging for years, only few studies have compared
CT and FDG PET/low dose CT (FDG PET/CT) with sur-
gery as reference standard. Even fewer of these studies
have examined the reproducibility of their results.
The purpose of this study was to examine and com-
pare CT versus integrated FDG PET/CT for mediastinalstaging in NSCLC, and the desire was to safely distin-
guish between malignant and benign lesions without
the need for invasive procedures. This would have a
significant diagnostic impact on patient management.
The hypothesis was that FDG PET/CT was more sensitive
and more specific than CT for staging the mediastinum.
First, the overall mediastinal staging results of CT and
FDG PET/CT were compared. Second, the staging results
of FDG PET/CT were examined in patients with and




The study conformed to Danish legal requirements. As
all subjects received best patient care and no biological
material was involved, and as all images were entirely
unidentifiable and there were no details on individuals
reported within the manuscript, Institutional Review Board
approval and individual informed consent for publication
of images were waived (The Central Denmark Region
Committees on Biomedical Research Ethics, case no.
1-15-0-72-2-09).
Study population
Patients, who were recently diagnosed with NSCLC and
were ready for staging, were prospectively identified for
inclusion over a 2-year study period. All patients received
CT as well as FDG PET/CT, and all metastasis suspect
lesions were biopsied. Based on all available data, that
is the CT, the FDG PET/CT and the biopsy results, a
multidisciplinary staging was made: If the patients were
staged with T1, N0, M0 disease, they received surgery.
If the patients were staged with T2-T4, N0-N3, M0
disease, they received a preoperative mediastinoscopy;
if they were eventually staged with T2-T4, N0-N1, M0
disease, they received surgery. In all other instances the
patients received oncological treatment.
114 consecutive patients received CT as well as FDG
PET/CT, and tissue sampling was obtained on all patients.
Patient sampling preceded both imaging and reference
standard. Therefore the study design was prospective.
CT and FDG PET/CT procedures
As a part of a fast-track work-up for lung cancer, the
patients received CT and FDG PET/CT within few days,
immediately followed by tissue sampling.
CT included the chest and the upper abdomen. CT
was performed with a multiple-row detector CT scanner
(Philips Brilliance CT 64-channel scanner; Philips Health-
care, Best, the Netherlands). CT acquisition parameters
were: 64 × 0.625 mm collimation. Reconstruction pa-
rameters were: 2.0 mm section thickness, and 1.0 mm
increment. Iodixanole 270 mg/ml (Visipaque® 270; GE
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paque® 300; GE Healthcare, Oslo, Norway), was injected
intravenously in weight-adjusted doses of 2 ml/kg body
weight to compensate for differences in distribution
volume. A bolus tracking technique was used to com-
pensate for differences in cardiac output. The trigger
ROI was placed in the Aorta and when it exceeded 200
HU, the patients were scanned from the root of the
neck to the upper abdomen including the liver and
adrenals. CT was performed after a delay of 15 seconds
for the chest, and 65 seconds for the upper abdomen,
and raw picture data sets were transferred to a Philips
Extended Brilliance™ Workspace workstation v4.02, where
they were reviewed with the application CT-viewer.
Two consultant radiologists reviewed the studies. The
reviewers were blinded to patient name, patient ID and
clinical data. Lymph nodes were characterised as normal-
sized or enlarged; a short axis diameter ≥ 1 cm on a trans-
verse CT scan was considered enlarged. Mediastinal staging
was done on a per-patient basis, in accordance to the
seventh edition of the TNM classification of malignant
tumours [3] (Figure 1). Both radiologists reviewed all
participants’ images side by side, to obtain consensus
results for the study. Six months later, they reviewed
the first 100 participants' images again, individually, to
assess reproducibility.
Whole body FDG PET/CT including the head except for
the brain, neck, thorax, abdomen, pelvis and thighs was
performed with an integrated PET/CT scanner (Siemens
Biograph w. 40-slice CT scanner; Siemens Healthcare,
Erlangen, Germany). Participants were instructed to submitFigure 1 This figure illustrates an enlarged ipsilateral hilar lymph
node (N1 lymph node) in NSCLC. The imaging modality is CT.to 6 hours of fasting prior to the examination. Approxi-
mately 400 MBq FDG was injected intravenously. FDG
PET/CT scans were performed after a delay of 60 minutes.
The FDG PET images were corrected for scatter and
iteratively reconstructed. CT acquisition parameters were:
40 × 3.0 mm collimation. Reconstruction parameters
were: 5.0 mm section thickness, and 3.0 mm increment.
No contrast medium was administered. FDG PET/CT
picture data sets were transferred to a Hermes Gold 3™
workstation, where they were reviewed with the appli-
cation Hermes Hybrid Viewer.
Two consultants in nuclear medicine did the FDG
PET/CT reviews. The reviewers were blinded to patient
names, patient IDs and clinical data. According to inter-
national guidelines [4,5], FDG uptake was compared to
the background uptake of the liver. Thus, lymph node
uptake was rated on a scale of 1 to 3: 1) no uptake, 2)
probably increased uptake and 3) definitely increased
uptake. A rating of 1 was considered normal, a rating of
2 or 3 was considered abnormal. Mediastinal staging
was done on a per-patient basis, in accordance to the
seventh edition of the TNM classification of malignant
tumours [3] (Figure 2). Low dose CT images were used
for attenuation correction, lesion location and measuring
purposes only. Both nuclear medicine consultants reviewed
all participants’ images side by side to obtain consensus
results for the study. Six months later, they reviewed
the first 100 participants’ images again, individually, to
assess reproducibility.
The radiologists had no access to FDG PET/CT images,
and the nuclear medicine physicians had no access to CT
images. Thus, the reviewers were completely blinded.Reference standard
Tissue sampling from the patients’ mediastinums was the
reference standard in this study. In patients who did not
receive surgery, tissue sampling was obtained by preopera-
tive mediastinoscopy with sampling from nodal stations 1,
2R/L, 3A, 4R/L, and 7; if necessary, it was obtained by
anterior mediastinotomy from nodal stations 5, and 6.
All mediastinoscopies/-tomies were guided by both CT
and FDG PET/CT examinations. In patients, who received
surgery, tissue sampling was obtained by complete lymph
node resection (i.e. resection of all visible and palpable
mediastinal and hilar lymph nodes from nodal stations
2R, 4R, 7, 8, 9, 10, 11+ for right-sided tumours, and 5, 6,
7, 8, 9, 10, 11+ for left-sided tumours).Statistics
According to the significance of involvement of N2 or
N3 lymph nodes, all participants were classified as having
either positive (N2 or N3) or negative (N0 or N1) staging
results and as having or not having mediastinal lymph node
Figure 2 This figure illustrates definitely increased FDG uptake of ipsilateral mediastinal and aortic lymph nodes (both, N2 lymph nodes) in
NSCLC. The imaging modality is FDG PET/CT.
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Three statistical methods were used to describe the data:
First, diagnostic accuracy was defined as the area under
the parametric Receiver Operating Characteristic (ROC)
curve, and was computed using the ratings with a max-
imum-likelihood ROC model assuming bivariate normal
distributions [6].
Second, sensitivity, specificity, positive predictive value,
and negative predictive value were computed from the
resulting 2×2 contingency tables. False positive rate
(1 – specificity), and false negative rate (1 – sensitivity)
were also computed.
Third, the reproducibility of the results was assessed
with weighted kappa of the original ratings.
Sample test statistics was used when appropriate;
Spearman’s rho was used to test for correlation between
ordered categorised (ordinal) variables. The chi-square test
was used to test for non-independence of the areas under
the ROC curves of CT and FDG PET/CT. P-values < 0.05
were considered statistically significant, and p-values <
0.001 were considered highly statistically significant.
The licensed statistical software package STATA/SE 11




114 patients participated in the study. 89 of these patients
received surgery with complete lymph node resection; 25
received mediastinoscopy/-tomy only. The nodal stage
distribution was 61% (69/114) N0, 13% (15/114) N1, 23%
(26/114) N2, and 4% (4/114) N3.
There was no significant difference between the areas
under the ROC curves of CT and F- 18-FDG PET/CT
(χ2 = 0.53; p = 0.47) (Figure 3). However, whereas CT re-
sults were significantly associated to reference standard
results (ρ = 0.29; p = 0.002), FDG PET/CT results were
not (ρ = 0.16; p = 0.08).CT and FDG PET/CT ratings are presented in wide
layout below (Table 1).
CT correctly classified 65% (74/114) of the cases; 27%
(31/114) were falsely overstaged, and 7% (9/114) were
falsely understaged. The overall sensitivity and specificity
of CT for mediastinal staging were 70%, and 63%, re-
spectively (Table 2). Reproducibility of the CT stagings
was substantial (κ = 0.63 (0.47 to 0.77)).
FDG PET/CT correctly classified 68% (77/114) of the
cases; 19% (22/114) were falsely overstaged, and 13%
(15/114) were falsely understaged. The overall sensitivity
and specificity of FDG PET/CT for mediastinal staging
were 50%, and 74%, respectively (Table 2). Reproducibil-
ity of the FDG PET/CT stagings was moderate (κ = 0.57
(0.39 to 0.72)).
The false positive rates of CT and FDG PET/CT were
37%, and 26%, respectively; the false negative rates were
30%, and 50%, respectively. The false negative lymph
nodes were located to stations 3A, 4R/L, and 7; this was
irrespective of imaging modality.
Stratified results
Next, CT results were used to stratify FDG PET/CT
results into subgroups.
In patients with enlarged lymph nodes on CT (n = 52),
the sensitivity and specificity of FDG PET/CT were 67%,
and 55%, respectively; the false positive rate was 45%
(Table 3).
In patients without enlarged lymph nodes on CT (n =
62), the sensitivity and specificity of FDG PET/CT were
11%, and 85%, respectively; the false negative rate was
89% (Table 3).
Discussion
The aim of this study was to examine and compare CT
versus integrated FDG PET/CT for mediastinal staging
in NSCLC, and the desire was to safely distinguish be-
tween malignant and benign lesions without the need
Figure 3 These two parametric ROC curves illustrate the overall mediastinal staging results of CT and FDG PET/CT. In this study the
overall diagnostic accuracy of CT and of FDG PET/CT was defined as the area under the parametric ROC curves. The two Roc curves were
compared using the chi-square test.
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PET/CT was more sensitive and more specific than CT
for staging the mediastinum. For this purpose, 114 par-
ticipants with NSCLC were included in a prospective
cohort study. Blinded CT and FDG PET/CT images
were reviewed. The participants’ mediastinums were
staged based on lymph node sizes (CT), or on FDG
uptake (FDG PET/CT). Reference standard was tissue
sampling. Overall diagnostic accuracy was defined as
the area under the ROC curve, and sensitivity, specifi-
city, positive predictive value, and negative predictive
value were calculated. Reproducibility was measured
with kappa statistics.Table 1 CT and FDG PET/CT ratings
Reference std. N0/N1 N0 (CT) N1 (CT) N2 (CT) N3 (CT) Total
N0 (FDG PET/CT) 31 7 8 8 54
N1 (FDG PET/CT) 5 2 0 1 8
N2 (FDG PET/CT) 3 1 7 2 13
N3 (FDG PET/CT) 4 0 1 4 9
Total 43 10 16 15 84
Reference std. N2/N3 N0 (CT) N1 (CT) N2 (CT) N3 (CT) Total
N0 (FDG PET/CT) 4 3 3 3 13
N1 (FDG PET/CT) 1 0 1 0 2
N2 (FDG PET/CT) 0 1 7 4 12
N3 (FDG PET/CT) 0 0 0 3 3
Total 5 4 11 10 30
Paired CT (columns) and FDG PET/CT (rows) ratings when the reference std.
was either N0/N1 or N2/N3.The overall prevalence of N2 or N3 disease was 26%.
Overall, there was no significant difference between CT
and FDG PET/CT staging results. As such, approximately
two-thirds of the patients were correctly staged by using
either CT or FDG PET/CT; the remaining one-third of
the patients was incorrectly staged. Whereas CT tended
to overstage the mediastinal nodes, FDG PET/CT tended
to both overstage and understage these. The sensitivity
and specificity of CT were 70%, and 63%, respectively, and
the sensitivity and specificity of FDG PET/CT were 50%,
and 74%, respectively. When the false positives and false
negatives were reviewed, it was noteworthy that whereas
the false positive rates of both CT and FDG PET/CT were
approximately 30% to 33%, the false negative rate of FDG
PET/CT was as high as 50%. Based on these results two
important messages emerged. First, approximately one-third
of all benign nodes are falsely deemed to be malignant,
irrespective of the imaging modality. Second, as many as
half of all malignant nodes are falsely deemed to be benignTable 2 Overall results of CT and FDG PET/CT (n = 114)
CT FDG PET/CT
Sensitivity 70% (51% to 85%) 50% (31% to 69%)
Specificity 63% (52% to 73%) 74% (63% to 83%)
Positive predictive value 40% (27% to 55%) 41% (25% to 58%)
Negative predictive value 86% (74% to 93%) 81% (70% to 89%)
False positive rate 37% 26%
False negative rate 30% 50%
Derived from Table 1. Results are presented as estimates with 95%
confidence intervals.
Table 3 Stratified results of FDG PET/CT, in patients
With enlarged lymph
nodes (n = 52)
Without enlarged
lymph nodes (n = 62)
Sensitivity 67% (43% to 85%) 11% (0% to 48%)
Specificity 55% (36% to 73%) 85% (72% to 93%)
Positive
predictive value
50% (31% to 69%) 11% (0% to 48%)
Negative
predictive value
71% (49% to 87%) 85% (72% to 93%)
False positive rate 45% 15%
False negative rate 33% 89%
Derived from Table 1. Results are presented as estimates with 95%
confidence intervals.
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overstage and understage the mediastinal nodes.
Next, the presence of enlarged lymph nodes on CT
was used to stratify FDG PET/CT results into subgroups.
If there were enlarged lymph nodes on CT, the number of
true positives (sensitivity) and false positives of FDG PET/
CT increased. Thus, in patients with enlarged lymph
nodes, FDG PET/CT is more likely to reveal both true
positive findings that are due to lymph node metastasis
and false positive findings that are due to infection or
inflammation, respectively. However, because the negative
consequences of false positives are so serious, a positive
FDG PET/CT should not automatically “rule in” N2 or N3
disease, and these patients should receive a mediastinos-
copy, unless distant metastases were proven beforehand.
Failure to do so could result in patients with surgically
resectable disease being denied curative surgery. In fact, in
that context, an FDG PET/CT examination would make
no difference to this group of patients. Conversely, if there
were no enlarged lymph nodes on CT, the number of true
negatives (specificity) of FDG PET/CT rose substantially,
but there was excessive 89% false negatives! Whether a
negative FDG PET/CT would obviate the need for me-
diastinoscopy in these patients has been controversial,
though according to our results, it would not. In that
context, an FDG PET/CT examination would not make
any difference to these patients either.
These results are somewhat controversial, considering
that the general agreement is that FDG PET is both
highly accurate for mediastinal staging of NSCLC, and
that it is superior to CT. In two large meta-analyses of
articles on the matter published since the mid 1990s
[1,2], it is claimed more than once that FDG PET has
both sensitivity and specificity for mediastinal staging of
NSCLC of almost 90%. Although the overall prevalence
of N2 and N3 disease of our study (26%) is almost
exactly identical to the prevalence in these meta-analyses
(29% and 32%, respectively), we are nowhere near their re-
sults. Most likely some or all of the studies included in the
meta-analyses represent highly selected study participantswhereas our study is set in our everyday clinical population.
Thus, our results seem to be more related to the results
from some newer studies on the matter [7-12].
There are some limitations to our study, the most
important being whether all mediastinal lymph node
metastases were detected by the reference standard.
Especially in the patients that were only examined with me-
diastinoscopy/-tomy this could be an issue. The diagnostic
yield of mediastinoscopy/-tomy is operator dependent, and
the false negative rate is estimated to be between 3% and
20% [1]. However, considering that these procedures were
only used to confirm N2 or N3 disease, they were accepted
as reference standard.
Since this study was carried out, mediastinoscopy has
been replaced by Endobronchial Ultrasound with Trans-
bronchial Needle Aspiration (EBUS-TBNA) and Endo-
scopic Ultrasound with Needle Aspiration (EUS-FNA),
due to these methods’ attractive combination of high
diagnostic yield and low risk. EBUS-TBNA is a relatively
new technique for mediastinal staging, which can be
performed on an outpatient basis. EBUS-TBNA can be
used to sample nodal stations 1, 2R/L, 4R/L, 7, 10R/L,
11R/L and 12R/L. In eight studies of EBUS-TBNA of the
mediastinum, the sensitivity was 79% to 95% (median,
90%) and the false negative rate was 1% to 37% (median,
24%) [13]. EUS-FNA of mediastinal lymph nodes through
the wall of the oesophagus can also be performed on
an outpatient basis. No mortality has been reported.
EUS-FNA is particularly useful for nodal stations 4 L,
5, 7, 8 and 9. In 16 studies of EUS-FNA of the mediasti-
num, the sensitivity was 45% to 100% (median, 84%) and
the FNR was 0% to 61% (median, 19%) for the detection
of N2 or N3 malignant mediastinal lymph nodes [13].
Conversely some important strength to our study must
be mentioned. First, patient sampling preceded both im-
aging and reference standard. This prospective design is a
strength, as well as the blinding procedure, as the STARD
statement from 2003 dictates that these are both natural
requisites in studies of diagnostic accuracy [14]. Further-
more, there is the large study size: 114 participants with
NSCLC were included, and all participants were examined
with both CT and with FDG PET/CT. This should be
compared to an average study size of 118 participants for
CT, and 65 participants for FDG PET [1], and 51 partici-
pants for both CT and FDG PET [2], making this study
comparably strong. Ultimately, all results in this study
were controlled for reproducibility. Though this has been
standard for CT since the STARD statement, to the best
of our knowledge, reproducibility has not previously been
controlled for FDG PET/CT.
Conclusions
In conclusion, controversially, CT was superior to FDG
PET/CT for mediastinal staging of NSCLC in more ways
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than for FDG PET/CT, and more importantly, that the
number of false negatives of CT was lower than for FDG
PET/CT. However, we also found that neither CT nor
FDG PET/CT could obviate the need for further invasive
staging prior to thoracotomy in patients with NSCLC;
for that purpose, the results of both modalities were too
meagre. Finally, we found that FDG PET/CT was not
clinically feasible for staging the mediastinum - regard-
less of whether the patients had or did not have enlarged
lymph nodes on CT.
An important clinical perspective of this study is that,
according to our results, neither CT nor FDG PET/CT,
individually or in combination, can obviate the need for
invasive staging prior to thoracotomy. This is regardless of
whether the patients to be staged are unselected or if they
are initially CT scanned, and then FDG PET/CT scanned.
There are too many false positives and especially too many
false negatives. Therefore, these patients still depend on
invasive staging methods. In our study, invasive staging
was accomplished by mediastinoscopy. However, today
this is increasingly replaced by EBUS or EUS [13].
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